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Antiviral and antioxidantAbstract Hydroxy marilone C is a bioactive metabolite produced from the culture broth of Strep-
tomyces badius isolated from Egyptian soil. Hydroxy marilone C was purified and fractionated by a
silica gel column with a gradient mobile phase dichloromethane (DCM):methanol then Sephadex
LH-20 column using methanol as a mobile phase. It was subjected to many procedures such as
infrared (IR), nuclear magnetic resonance (NMR), Mass spectroscopy (MS) and UV spectroscopy
for elucidation of its structure. It was evaluated for antioxidant, cytotoxicity against human alve-
olar basal epithelial cell line (A-549) and human breast adenocarcinoma cell line (MCF-7) and
antiviral activities; showed that the maximum antioxidant activity was 78.8% at 3 mg/ml after
90 min. and the IC50 value against DPPH radical found about 1.5 mg/ml after 60 min. Using
MTT assay the effect of the pure compound on the proliferation of A-549 cells and MCF-7 cells
was 443 lg/ml and 147.9 lg/ml, respectively, while for detection of antiviral activity using
Madin–Darby canine kidney (MDCK) cells the maximum cytotoxicity was at 27.9% and IC50
was 128.1 lg/ml. The maximum concentration required for protecting 50% of the virus-infected
cells against H1N1 viral cytopathogenicity (EC50) was 33.25% for 80 lg/ml. These results indicated
that the hydroxy marilone C has potential antitumor and antiviral activities.
 2016 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Among all known producers of small molecule natural prod-
ucts, microorganisms represent a rich source of biologically
active secondary metabolites that find wide-ranging applica-
tions as antibiotics, immunosuppressant’s, antiparasitics,antiviral and anticancer agents [1]. Secondary metabolites are
excreted by microbial cultures at the end of primary growth
and during the stationary phase of growth. Secondary metabo-
lites are compounds neither essential for growth nor key inter-
mediates of the organism’s basic metabolism but presumably
playing some other role in the life of microorganisms. They
are usually found as a mixture of closely related molecules with
a peculiar and rare chemical structure [2,3]. Streptomyces spp.
are widespread in nature and continue to have a significant
162 O.H. El Sayed et al.role in the production of novel secondary bioactive metabo-
lites. Streptomyces spp. produce many classes of secondary
metabolites with great biofunctional diversity that may ulti-
mately find application as antibiotics, antifungal, antiviral,
anticancer, immunosuppressants, insecticides, herbicides etc.
and diverse chemical structures, which makes them useful as
pharmaceuticals and agricultural agents [4,5]. However, the
search for novel drugs is still a priority goal for cancer therapy,
due to the rapid development of resistance to multiple
chemotherapeutic drugs. In addition, the high toxicity usually
associated with cancer chemotherapy drugs and their undesir-
able side effects increase the demand for novel antitumor drugs
active against untreatable tumors, with fewer side effects and/
or with greater therapeutic efficiency [6]. About 7.6 million
deaths worldwide were due to cancer with 12.7 million new
cases per year being reported worldwide. Traditional treat-
ments of cancer inaccessible to surgery are multi-modal com-
prising chemotherapy, immunotherapy, hormonal therapy
and radiotherapy. Although, there have been improvements
in cancer patient survival by employing cytotoxic chemothera-
peutic regimens, this approach is encumbered by poor accessi-
bility of medications to tumor site and non-specific
cytotoxicity to normal cells [7]. The clinical treatment methods
against cancer include: surgery, which is local excision of
tumor; radiotherapy, which eliminate tumor by exposing to
radiation; chemotherapy, which relies on drug targeting tumor
cells; combined modality therapy, which includes all three for-
mer treatments together; and immunotherapy, which evokes
an immune response against tumor [8]. Natural products have
not only yielded new and effective drugs, but they have also
provided insight into new mechanisms of action, and cancer
treatment would be immeasurably poorer without the insights
and the compounds provided from nature. The reasons for the
effectiveness of natural products are at least twofold. In the
first place, there is a high correlation between the properties
of drugs and those of natural products. Second, natural prod-
ucts usually have built-in so; it can bind to complex proteins
and other three-dimensional biological receptors [9].
So, this work aimed at isolation of a bioactive secondary
metabolite from Streptomyces badius and usage of several tech-
niques to identify this metabolite. Therefore, it was tested as
antioxidant, anticancer and antiviral compound.
2. Materials and methods
2.1. Fermentation and extraction of bioactive compounds
S. badius (M7) isolated from Egyptian soil capable to give
highest antioxidant and antitumour activities [10] was selected
for production of the bioactive compound. Every one liter
Erlenmeyer flask contained 250 ml of ISP2 medium (g/L): malt
extract 10; yeast extract 4; glucose 20 at pH 7.0 [11] and was
inoculated with a piece having 0.5 cm diameter of a well-
grown agar subculture of the strain [12]. Thirty flasks were
kept at 28 C using a rotary shaker (150 rpm) and harvested
after 7 days. After harvesting and centrifugation at 5000 rpm
for 15 min, the supernatant of each flask was extracted by ethyl
acetate, and then separated from the water phase using a sep-
arating funnel. Ethyl acetate extracts were concentrated in vac-
uum tell dryness, yielding 4.5 g of a reddish brown crude
extract.2.2. Purification of bioactive compounds
The obtained extract was applied to column chromatography
on silica gel G254 eluted by a gradient of dichloromethane
(DCM) and methanol and the drops at the bottom of the col-
umn were collected and the fractions were analyzed using
TLC. The fractions collected at the end of the fractionation
process on the silica gel column showed varied biological anti-
tumour activity using Ehrlich Ascites Carcinoma cells
(EACC). The fraction have high antitumour activity was
loaded on the top of the Sephadex LH-20 column and metha-
nol was the mobile phase. Every individual fraction of bioac-
tive residue was collected at the end of fractionation process
on a Sephadex LH-20 column. These fractions showed varied
biological antitumour activity. Fraction have high antitumour
activity was also subjected to separate and purify using prepar-
ative TLC. The plates were prepared by slurring 30 g of silica
gel Type 60 F254; (Merck) in 60 ml distilled water. The com-
pounds were detected from their UV absorbance at 254 and
366 nm and by spraying the TLC plates with anisaldehyde/sul-
furic acid reagent giving different colored reactions with many
structural elements [13].
2.3. Spectral measurements
The elucidation of the chemical structures of the promising
active compound had been done using several instruments as
infrared (FTIR), mass, nuclear magnetic resonance (NMR)
and UV spectroscopy. An IR spectrum of the pure compound
was performed with KBr pellets, 2.0 mg sample and 200 mg
KBr using the FTIR-UNIT Bruker Vector 22 Spectrophotome-
ter. NMR (1H and 13C NMR) were obtained on JEOL-ECA
500 MHz spectrometer using TMS as internal standard, the
chemical shifts were expressed in d (ppm) and coupling con-
stants J in Hz. Mass spectra were recorded on thermo
scientific-trace GC Ultra, USA. Coupled with single quadru-
pole MS, temperature (0–300 C) and UV spectroscopy were
recorded on a Shimadzu UV-2401 PC double beam spec-
trophotometer using 1.0 cm quartz cells according to Paterson
and Kemmelmeier 31. These experiments were carried out in
central services laboratory at National Research Centre, Egypt.
2.4. Biological activity
2.4.1. Antioxidant activity
The free radical scavenging activity (RSA) of the active sec-
ondary metabolite was assessed by the decoloration of chloro-
form solution of DPPH (1,1-diphenyl-2-picrylhydrazyl) radical
(violet color) according to [14]. The scavenging activity of free
radical by active compound was evaluated spectrophotometri-
cally at 517 nm. The scavenging activity was calculated as
follows:
Scavenging abilityð%Þ¼ A517 of controlA517 of sample=A517 of control
 
100:2.4.2. Assay of the antitumor activity against different cell lines
Cytotoxicity against the two tumor cell lines, human breast
Aden carcinoma cell line (MCF-7) and human alveolar basal
Figure 1 Antitumor activity of Streptomyces badius (M7)
secondary metabolites fractionated from silica gel column.
Figure 2 Antitumor activity of F3 sub-fractions from Sephadex
LH-20 column.
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USA, were used to evaluate the cytotoxic effect of the tested
samples using MTT cell viability assay according to [15]. Cells
(0.5  105 cells/well), in serum-free media, were plated in a flat
bottomed 96-well micro plate, and treated with 20 lL of differ-
ent concentrations of the tested sample for 48 h at 37 C, in a
humidified 5% CO2 atmosphere. After incubation, media were
removed and 40 ll MTT solution/well were added and incu-
bated for an additional 4 h. MTT crystals were solubilized
by adding 180 ll of acidified isopropanol/well and plate was
shacked at room temperature, followed by photometric deter-
mination of the absorbance at 570 nm using micro plate
ELISA reader. Triplicate repeats were performed for each con-
centration and the average was calculated. Data were
expressed as the percentage of relative viability compared with
the untreated cells compared with the vehicle control, with
cytotoxicity indicated by <100% relative viability. Percentage
of relative viability was calculated using the following
equation:
½Absorbance of treated cells=Absorbance of control cells100
Then the half maximal inhibitory concentration (IC50) was
calculated from the equation of the dose–response curve.
2.4.3. Antiviral assays
The antiviral activity of the compounds was determined
against A/Puerto Rico/8/1934 (PR8) H1N1 virus. Stock solu-
tions of the test compounds were prepared in DMSO. Cells
grown to confluence in 96-well plates were infected with
100 lL of 100 TCID50 viruses. After an adsorption period
of 1 h at 37 C, virus was removed and serial dilutions of the
compounds were added. Maintenance DMEM with 2% FBS
was added (100 ll/well). The cultures were further incubated
at 37 C for 3 days, until complete CPE was observed in the
infected and untreated virus control. The determination of
the anti-H1N1 virus activity of the compounds was based on
virus-induced cytopathogenicity of H1N1 infected MDCK
cells, measured at day 4 post virus infection by the MTT col-
orimetric method [16,17]. An absorbance of formazan was
detected by a multi-well plate reader at 540 nm with 620 nm
reference wavelength. The results were expressed as the 50%
effective concentration (EC50). The 50% effective antiviral
concentration (EC50) was defined as the compound concentra-
tion required for protecting 50% of the virus-infected cells
against viral cytopathogenicity.
3. Results
3.1. Isolation of hydroxy marilone C
After evaporation of the organic phase 4.5 g of brown oily
extract was obtained. The extract was fractionated by silica
gel column yielding five fractions (F1, F2, F3, F4 and F5).
Each single fraction was assessed to determine the antitumor
activity (by Ehrlich ascites carcinoma). Fig. 1 showed that
F3 was the highest fraction showing an inhibition ratio to
the Ehrlich cells of 67.05%. F3 was fractionated by Sephadex
LH-20 column using methanol as a mobile phase to yield six
fractions (F3F1, F3F2, F3F3, F3F4, F3F5 and F3F6). All
six sub-fractions screened using Ehrlich cells showed that allsub-fractions which separated from fraction F3 have anti-
tumor activities in different percents except F3F4 which has
no activity. Thus, sub-fraction F3F1 was the highest fraction
showing an inhibition ratio to the Ehrlich cells of 69.98%
(Fig. 2). Sub-fraction F3F1 was separated by preparative thin
layer chromatography. Fig. 3 showed that sub-fraction F3F1b
was the highest fraction showing an inhibition ratio to the Ehr-
lich cells of 67.57%. So, it was selected as an active purified
compound for further experiments.
3.2. Structure elucidation of hydroxy marilone C
The active sub-fraction F3F1b isolated from S. badius (M7)
was obtained as a light yellow oily compound insoluble in
water while soluble in methanol, hexane, ethyl acetate, chloro-
form and dichloromethane. The isolated compound gave a
positive reaction (purple color) with concentrated H2SO4. It
appeared as a single spot on the TLC Merck Kiesel gel 60
F254 (Rf: 0.62 with solvent system DCM:methanol 9:1) under
long wave length UV light (365 nm). It was investigated by
IR, NMR (1H and 13C NMR), MS and UV spectroscopy.
The ultraviolet (UV) absorption spectrum recorded a
Figure 3 Antitumor activity of sub-fractions from preparative
TLC.
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methane, kmax = 207 nm with methanol and kmax = 242 with
chloroform as shown in Fig. 4.
Fig. 5 showing the Mass spectrum revealed that the molec-
ular formula is C20H26O5 and the molecular weight is
346 g/mol. and showed a fragment at m/z 279.3 due to loss
(C5H7) from the side chain followed by a fragment at m/z
261.3 (279–OH&H) and the base beak at m/z 57.14 resulting
from cleavage of ring (A) after loss OH to give an ionic frag-
ment [C2O2H]
+. The 13C NMR and 1H NMR spectrum were
obtained at 500 MHz in CDCl3 solution listed in Table 1.
The IR spectrum of the sub-fraction (Fig. 6) showed char-
acteristic bands corresponding to 3425 cm1 indicated as
(OH), 1730 cm1 indicated as (C‚O), 1633 cm1 indicated
as (C‚C), 1116 cm1 indicated as gemdimethyl and
1453 cm1 indicated as (OCH3).
The obtained data, UV, IR, MS, 13C NMR and 1H NMR
suggested that the isolated compound is very close to marilone
C, but the OH group shown at 3425 cm1 at IR spectrum andFigure 4 UV spectrum of purified su7.5 ppm at 1H NMR indicated the presence of the OH group
on the furan ring (A) at position 1. So, from these available
data the suspected structure of this compound was shown at
Fig. 7.
3.3. Biological evaluation of hydroxy marilone C
DPPH free radical scavenging activity technique was used to
determine quantitatively the antioxidant activity at different
times (30, 60 and 90 min.). By increasing the concentrations
of the compound from 100 to 3000 lg/ml the total antioxidant
activity was increased. Maximum antioxidant activity was
78.8% at 3000 lg/ml after 90 min. The IC50 value against
DPPH radical was found to be about 1500 lg/ml after
60 min. Fig. 8.
The effect of the hydroxy marilone C on the proliferation of
A-549 cells and MCF-7 cells was studied after 48 h of incuba-
tion. As shown in (Figs. 9 and 10), respectively, the treatment
of MCF-7 cells was more cytotoxic-sensitive than treatment of
A-549. As shown in (Fig. 11) the calculated IC50 for cell line
MCF-7 was 147.9 lg/ml, while the other cell line A-549
showed a weak cytotoxic level as concluded from the high
calculated IC50 values – indicating low anti-tumor affinity –
to be 443 lg/ml.
The cytotoxicity of different concentrations of hydroxy
marilone C by increasing the concentrations from 20–80 lg
the cytotoxicity of the pure compound is increased and showed
maximum cytotoxicity at 27.9%. Also, the concentration
required to cause a microscopically detectable alteration of
normal cell morphology (IC50) was 128.1 lg/ml (Table 2).
The antiviral activity of the hydroxy marilone C was
determined against A/Puerto Rico/8/1934 (PR8) H1N1 virus
and the concentration of hydroxy marilone C required for
protecting 50% of the virus-infected cells against viral
cytopathogenicity (EC50). The maximum EC50 of the hydroxy
marilone C was 33.25% for 80 lg/ml as effective concentration
of the hydroxy marilone C.b-fraction F3F1b with chloroform.
Figure 5 MS spectrum of purified sub-fraction F3F1b.
Table 1 1H NMR and 13C NMR spectrum data.
Position 1H
NMR d,
ppm
13C
NMR d,
ppm
Position 1H
NMR d,
ppm
13C
NMR d,
ppm
1 7.53 78.49 1n 4.65 65.32
2 – 128.31 2n 5.34 122.67
3 – 153.18 3n – 141.43
4 – 124.44 4n 2.28 40.64
5 – 159.94 5n 2.29 29.43
6 7.24 0.87 6n 5.12 125.81
7 – 126.53 7n – 132.90
8 – 168.02 8n 1.24 23.26
9 3.48 60.85 9n 1.41 20.03
10 2.56 10.46 10n 0.87 22.78
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There are two reasons for the effectiveness of secondary
metabolites, the first, there is a high correlation between the
properties of drugs and those of secondary metabolites.
Second, secondary metabolits usually have built-in chirality,
and are thus uniquely suited to bind to complex proteins and
other three-dimensional biological receptors [18]. The ability
of Streptomyces species to produce antibiotics or related
secondary metabolites has attracted great interest among
researchers [19]. Ability is generally ascribed to the existence
of the clusters of the Streptomyces strains, which encodes
enzymes for a lot of secondary metabolic pathways [20].However, secondary metabolite production in microbes is also
strongly influenced by nutritional factors and growth condi-
tions [21]. The data obtained in the present study comprise
the isolation of hydroxy marilone C as a major bioactive
compound produced fot the first time from S. badiusM7. Mar-
ilones are phthalide derivatives which are organic chemical
compounds which are a class of structurally very diverse sec-
ondary metabolites with more than 180 naturally occurring
compounds or phytochemical compounds classified under lac-
tones [22,23]. Phthalides are known to provide health benefits
by stimulating various enzymes in the body [24]. Also, it exhi-
bits an equally broad spectrum of bioactivity [25].
Some phthalides having anticancer activity can enhance the
sensitivity of drug resistance of tumor cells against chemother-
apy and decrease the drug-resistance of tumor cells and
enhance notably several chemotherapy agent induced apopto-
sis of tumor cells [26]. Such phthalides isolated from Angelica
sinensis, have recently been found to be cytotoxic against sev-
eral brain tumor cell lines and leukemia cells and colon cancer
HT-29 [27] and they show anticancer activity against the HeLa
cancer cell line [28], while, phthalides isolated from Alternaria
porri were highly cytotoxic toward HeLa/cervical cancer and
KB/oral cancer cells [29].
A large scale-fermentation of the strain followed by
working up and purification using a series of chromatographic
techniques led to isolation of hydroxy marilone C which was
identified using intensive studies of different spectroscopic
means such as 1H NMR and 13C NMR, MS, UV and IR which
gave data similar to Almeida et al. [30] and suggested marilone
C as a name in these results.
Hydroxy marilone C was evaluated for antioxidant,
cytotoxic activity against two tumor cell lines (A-549 and
Figure 6 IR spectrum of purified sub-fraction F3F1b.
Figure 7 The suggested structure of purified sub-fraction F3F1.
Figure 8 Scavenging activity of pure compound at different
times.
Figure 9 Cytotoxic effect of different samples against A-549 cells
using MTT assay (n= 4), data are expressed as the mean value of
cell viability (% of control).
Figure 10 Cytotoxic effect of different samples against MCF-7
cells using MTT assay (n= 4), data are expressed as the mean
value of cell viability (% of control).
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Figure 11 IC50 at MCF-7 and A-549 cells using MTT assay.
Table 2 Cytotoxicity at different concentrations and IC50 for
pure compound.
Concentration (lg/ml) Cytotoxicity (%)
20 0
40 2.9
80 27.9
Production of hydroxy marilone C from Streptomyces badius 167MCF-7) and antiviral activities. The total antioxidant activity
of the hydroxy marilone C was increased by increasing the
hydroxy marilone C weight from 100 to 3000 lg, while, IC50
value against DPPH radical was found to be about 1500 lg
after 60 min. The DPPH assay used to determine antioxidant
activity was produced from Streptomyces sp. [31,32]. The treat-
ment of MCF-7 cells with hydroxy marilone C was more
cytotoxic-sensitive than treatment of A-549. The calculated
IC50 for the cell line MCF-7 was 147.9 lg/ml, while, the other
cell line A-549 showed IC50 indicating low anti-tumor affinity
to be 443 lg/ml for hydroxy marilone C. These results agree
with Almeida et al. [30] who showed that marilone C which
was tested for cytotoxic activity toward three cancer cell lines
(NCI-H460/lung, MCF7/breast and SF268/CNS) showed
antiproliferative activity with an average IC50 of 26.6 lM.
Wang et al. [33] isolated five new derivatives Streptomyces
sp. FXJ7.328 and showed that these derivatives have antiviral
activity against influenza A (H1N1) virus with an IC50 value of
41.5 ± 4.5 lM. Hydroxy marilone C concentration required
for protecting 50% of the virus-infected cells against viral
cytopathogenicity (EC50) was 17.5% with 40 lg as effective
concentration while the maximum EC50 was 33.25% with
80 lg as effective concentration. These results mentioned that
S. badius have an antiviral activity against A/Puerto
Rico/8/1934 (PR8) H1N1 virus.
So, the obtained data in this study showed S. badius (M7)
have the ability to produce bioactive compounds such as
hydroxy marilone C (phthalide derivative) for the first time
as a bioactive compound. This compound offers health bene-
fits and its antioxidant activity, anticancer activity and antivi-
ral activities are recorded.References
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